CHARLES RIVER LABORATORIES (CRL) Stock Fundamental Analysis
NYSE:CRL - New York Stock Exchange, Inc. - US1598641074 - Common Stock - Currency: USD
We assign a fundamental rating of 4 out of 10 to CRL. CRL was compared to 54 industry peers in the Life Sciences Tools & Services industry. Both the profitability and the financial health of CRL get a neutral evaluation. Nothing too spectacular is happening here. CRL has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
CRL had positive earnings in the past year.
CRL had a positive operating cash flow in the past year.
CRL had positive earnings in each of the past 5 years.
CRL had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
With a decent Return On Assets value of -0.92%, CRL is doing good in the industry, outperforming 61.11% of the companies in the same industry.
CRL's Return On Equity of -2.06% is fine compared to the rest of the industry. CRL outperforms 62.96% of its industry peers.
Looking at the Return On Invested Capital, with a value of 5.72%, CRL is in the better half of the industry, outperforming 72.22% of the companies in the same industry.
Measured over the past 3 years, the Average Return On Invested Capital for CRL is significantly below the industry average of 16.00%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.92% | ||
| ROE | -2.06% | ||
| ROIC | 5.72% |
ROA(3y)4.11%
ROA(5y)4.9%
ROE(3y)9.94%
ROE(5y)12.5%
ROIC(3y)7.32%
ROIC(5y)7.6%
1.3 Margins
CRL's Profit Margin has declined in the last couple of years.
With a decent Operating Margin value of 11.64%, CRL is doing good in the industry, outperforming 70.37% of the companies in the same industry.
In the last couple of years the Operating Margin of CRL has remained more or less at the same level.
The Gross Margin of CRL (35.03%) is worse than 62.96% of its industry peers.
CRL's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 11.64% | ||
| PM (TTM) | N/A | ||
| GM | 35.03% |
OM growth 3Y-8.72%
OM growth 5Y-1.4%
PM growth 3Y-71.55%
PM growth 5Y-51.64%
GM growth 3Y-2.67%
GM growth 5Y-1%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), CRL is destroying value.
CRL has less shares outstanding than it did 1 year ago.
Compared to 5 years ago, CRL has more shares outstanding
Compared to 1 year ago, CRL has an improved debt to assets ratio.
2.2 Solvency
CRL has an Altman-Z score of 2.19. This is not the best score and indicates that CRL is in the grey zone with still only limited risk for bankruptcy at the moment.
CRL has a Altman-Z score (2.19) which is comparable to the rest of the industry.
The Debt to FCF ratio of CRL is 4.04, which is a neutral value as it means it would take CRL, 4.04 years of fcf income to pay off all of its debts.
The Debt to FCF ratio of CRL (4.04) is better than 68.52% of its industry peers.
CRL has a Debt/Equity ratio of 0.70. This is a neutral value indicating CRL is somewhat dependend on debt financing.
CRL has a worse Debt to Equity ratio (0.70) than 74.07% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.7 | ||
| Debt/FCF | 4.04 | ||
| Altman-Z | 2.19 |
ROIC/WACC0.56
WACC10.16%
2.3 Liquidity
A Current Ratio of 1.36 indicates that CRL should not have too much problems paying its short term obligations.
CRL has a Current ratio of 1.36. This is in the lower half of the industry: CRL underperforms 77.78% of its industry peers.
A Quick Ratio of 1.10 indicates that CRL should not have too much problems paying its short term obligations.
The Quick ratio of CRL (1.10) is worse than 79.63% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.36 | ||
| Quick Ratio | 1.1 |
3. Growth
3.1 Past
CRL shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 4.49%.
Measured over the past years, CRL shows a quite strong growth in Earnings Per Share. The EPS has been growing by 8.93% on average per year.
CRL shows a decrease in Revenue. In the last year, the revenue decreased by -1.21%.
CRL shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 9.09% yearly.
EPS 1Y (TTM)4.49%
EPS 3Y-0.03%
EPS 5Y8.93%
EPS Q2Q%11.43%
Revenue 1Y (TTM)-1.21%
Revenue growth 3Y4.59%
Revenue growth 5Y9.09%
Sales Q2Q%0.59%
3.2 Future
Based on estimates for the next years, CRL will show a small growth in Earnings Per Share. The EPS will grow by 5.19% on average per year.
Based on estimates for the next years, CRL will show a small growth in Revenue. The Revenue will grow by 1.71% on average per year.
EPS Next Y-6.05%
EPS Next 2Y0.2%
EPS Next 3Y3.14%
EPS Next 5Y5.19%
Revenue Next Year-3.27%
Revenue Next 2Y-0.43%
Revenue Next 3Y1.39%
Revenue Next 5Y1.71%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
CRL is valuated correctly with a Price/Earnings ratio of 13.72.
Compared to the rest of the industry, the Price/Earnings ratio of CRL indicates a rather cheap valuation: CRL is cheaper than 94.44% of the companies listed in the same industry.
The average S&P500 Price/Earnings ratio is at 26.51. CRL is valued slightly cheaper when compared to this.
A Price/Forward Earnings ratio of 14.18 indicates a correct valuation of CRL.
Compared to the rest of the industry, the Price/Forward Earnings ratio of CRL indicates a rather cheap valuation: CRL is cheaper than 88.89% of the companies listed in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 34.09, CRL is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 13.72 | ||
| Fwd PE | 14.18 |
4.2 Price Multiples
CRL's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. CRL is cheaper than 98.15% of the companies in the same industry.
CRL's Price/Free Cash Flow ratio is rather cheap when compared to the industry. CRL is cheaper than 92.59% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 12.47 | ||
| EV/EBITDA | 10.52 |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)1.54
EPS Next 2Y0.2%
EPS Next 3Y3.14%
5. Dividend
5.1 Amount
CRL does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NYSE:CRL (8/11/2025, 12:30:06 PM)
146.915
-1.83 (-1.23%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners111.57%
Inst Owner Change-1.28%
Ins Owners0.91%
Ins Owner Change6.41%
Market Cap7.22B
Analysts66.96
Price Target164.47 (11.95%)
Short Float %4.76%
Short Ratio2.71
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)17.56%
Min EPS beat(2)11.44%
Max EPS beat(2)23.68%
EPS beat(4)4
Avg EPS beat(4)11.21%
Min EPS beat(4)4.03%
Max EPS beat(4)23.68%
EPS beat(8)8
Avg EPS beat(8)10.55%
EPS beat(12)12
Avg EPS beat(12)8.62%
EPS beat(16)16
Avg EPS beat(16)6.82%
Revenue beat(2)2
Avg Revenue beat(2)3.59%
Min Revenue beat(2)3.45%
Max Revenue beat(2)3.74%
Revenue beat(4)4
Avg Revenue beat(4)2.63%
Min Revenue beat(4)0.91%
Max Revenue beat(4)3.74%
Revenue beat(8)7
Avg Revenue beat(8)1.68%
Revenue beat(12)10
Avg Revenue beat(12)1.88%
Revenue beat(16)11
Avg Revenue beat(16)1.12%
PT rev (1m)4.78%
PT rev (3m)9.19%
EPS NQ rev (1m)0.04%
EPS NQ rev (3m)5.56%
EPS NY rev (1m)0%
EPS NY rev (3m)2.92%
Revenue NQ rev (1m)0.04%
Revenue NQ rev (3m)2.79%
Revenue NY rev (1m)0.03%
Revenue NY rev (3m)0.92%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 13.72 | ||
| Fwd PE | 14.18 | ||
| P/S | 1.79 | ||
| P/FCF | 12.47 | ||
| P/OCF | 9.16 | ||
| P/B | 2.15 | ||
| P/tB | N/A | ||
| EV/EBITDA | 10.52 |
EPS(TTM)10.71
EY7.29%
EPS(NY)10.36
Fwd EY7.05%
FCF(TTM)11.78
FCFY8.02%
OCF(TTM)16.03
OCFY10.91%
SpS82.02
BVpS68.27
TBVpS-3.77
PEG (NY)N/A
PEG (5Y)1.54
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.92% | ||
| ROE | -2.06% | ||
| ROCE | 7.24% | ||
| ROIC | 5.72% | ||
| ROICexc | 5.88% | ||
| ROICexgc | 13.43% | ||
| OM | 11.64% | ||
| PM (TTM) | N/A | ||
| GM | 35.03% | ||
| FCFM | 14.36% |
ROA(3y)4.11%
ROA(5y)4.9%
ROE(3y)9.94%
ROE(5y)12.5%
ROIC(3y)7.32%
ROIC(5y)7.6%
ROICexc(3y)7.59%
ROICexc(5y)7.91%
ROICexgc(3y)18.25%
ROICexgc(5y)19.94%
ROCE(3y)9.27%
ROCE(5y)9.62%
ROICexcg growth 3Y-14.69%
ROICexcg growth 5Y-4.68%
ROICexc growth 3Y-7.59%
ROICexc growth 5Y-3.19%
OM growth 3Y-8.72%
OM growth 5Y-1.4%
PM growth 3Y-71.55%
PM growth 5Y-51.64%
GM growth 3Y-2.67%
GM growth 5Y-1%
F-Score4
Asset Turnover0.53
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.7 | ||
| Debt/FCF | 4.04 | ||
| Debt/EBITDA | 2.59 | ||
| Cap/Depr | 48.58% | ||
| Cap/Sales | 5.19% | ||
| Interest Coverage | 4.15 | ||
| Cash Conversion | 87.57% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.36 | ||
| Quick Ratio | 1.1 | ||
| Altman-Z | 2.19 |
F-Score4
WACC10.16%
ROIC/WACC0.56
Cap/Depr(3y)90.89%
Cap/Depr(5y)85.95%
Cap/Sales(3y)7.21%
Cap/Sales(5y)6.76%
Profit Quality(3y)1669.68%
Profit Quality(5y)1049.89%
High Growth Momentum
Growth
EPS 1Y (TTM)4.49%
EPS 3Y-0.03%
EPS 5Y8.93%
EPS Q2Q%11.43%
EPS Next Y-6.05%
EPS Next 2Y0.2%
EPS Next 3Y3.14%
EPS Next 5Y5.19%
Revenue 1Y (TTM)-1.21%
Revenue growth 3Y4.59%
Revenue growth 5Y9.09%
Sales Q2Q%0.59%
Revenue Next Year-3.27%
Revenue Next 2Y-0.43%
Revenue Next 3Y1.39%
Revenue Next 5Y1.71%
EBIT growth 1Y-25.61%
EBIT growth 3Y-4.53%
EBIT growth 5Y7.56%
EBIT Next Year28.55%
EBIT Next 3Y12.77%
EBIT Next 5Y8.72%
FCF growth 1Y99.92%
FCF growth 3Y-1.94%
FCF growth 5Y8.06%
OCF growth 1Y25.98%
OCF growth 3Y-1.16%
OCF growth 5Y8.84%